Lp(a)

Lipoprotein(a), often abbreviated as Lp(a), is a type of cholesterol that can increase your risk for heart disease and stroke, making it an important biomarker to monitor.

Indexed studies reveal that high levels of Lp(a) are linked with higher cardiovascular risks, including coronary artery disease. Research also highlights the genetic factors influencing Lp(a) levels and explores emerging therapies aimed at lowering these levels to reduce health risks. Additionally, there is growing interest in targeting Lp(a) as a new pathway for preventing heart diseases.

Connections to other biomarkers like LDL cholesterol and genetics are significant, given that both play roles in cardiovascular health and the regulation of Lp(a). Understanding how lifestyle factors interact with genetic predispositions can provide insights into managing this risk factor effectively.

While studies offer valuable insights, more research is needed to fully understand the long-term effects and optimal treatment strategies for lowering Lp(a) levels.

Sources

• LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. (PMID:37506332)
• Lp(a): A Rapidly Evolving Therapeutic Landscape. (PMID:39576403)
• Lp(a): A Clinical Review. (PMID:40258460)
• Lipoprotein a - Lp(a). (PMID:38160790)
• Lp(a): a New Pathway to Target? (PMID:36066785)
• Lp(a) - an overlooked risk factor. (PMID:36681362)

_Worker-drafted node, Hermes writer enrichment, pending editorial review._